Boiling point: 777.6±70.0℃
The trade name for ticagrelor is Belinda. Round, biconvex, yellow-coated tablets, engraved with "T" on one side and "90" on the upper side and smooth on the other side, contain 90 mg of ticagrelor. Ticagrelor is a platelet aggregation inhibitor, and its clinical efficacy and safety have been validated and supported by the Platelet Inhibition and Patient Outcomes Outcomes Study and its multiple subgroups. Clopidogrel should only be used in patients who cannot use ticagrelor. Since ticagrelor and thienopyridine drugs (clopidogrel) are a different chemical class of drugs, the previous Chinese name "ticagrelor" was replaced by "ticagrelor".
This product is used for patients with acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction), including patients receiving drug therapy and percutaneous coronary intervention, to reduce thrombotic cardiac The incidence of vascular events. Compared with clopidogrel, this product reduced the incidence of the composite end point of cardiovascular death, myocardial infarction or stroke, and the difference between the two treatment groups was due to cardiovascular death and myocardial infarction, but there was no difference in stroke.
Ticagrelor is primarily eliminated by hepatic metabolism. The average recovery of radioactivity measured by the use of ticagrelor radiotracer was approximately 84% (57.8% in feces and 26.5% in urine). The recoveries of ticagrelor and its active metabolite in urine were both less than 1% of the administered dose. The main route of elimination of active metabolites is through bile secretion. The mean t1/2 of ticagrelor was approximately 7 hours and the active metabolite was 9 hours.